Chinese Team Develops Personalized Tumor Vaccine with Remarkable Results in Mice
A team of Chinese researchers, led by Profs. NIE Guangjun, WU Yan, and ZHAO Yuliang, has developed a novel personalized tumor vaccine using hybrid membrane nanovaccines. These vaccines combine tumor membrane antigens and bacterial inner membrane on polymer nanoparticles to activate dendritic cells and T cells.
The team's previous work includes innovative developments in nano-inhibitors targeting immune checkpoints and natural nano-vesicles with chimeric immune checkpoint PD1 antibody. Their latest platform focuses on designing novel delivery systems for tumor antigens with enhanced specificity and efficacy.
In mouse tumor models, the hybrid membrane-coated nanoparticles demonstrated remarkable results. They prevented tumor recurrence and provided long-term protection against tumor rechallenge. This suggests promising potential in human clinical trials.
The hybrid membrane nanovaccines, developed by Profs. NIE Guangjun, WU Yan, and ZHAO Yuliang, offer a personalized approach to tumor vaccination. By combining tumor membrane antigens and bacterial inner membrane, these vaccines aim to stimulate patients' immune response, specifically targeting and killing tumor cells. The success in mouse models paves the way for further exploration in human trials to inhibit postoperative tumor recurrence.
